Clinical trials: Diabetes Type I
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Diabetes Mellitus, Type 1
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
- Trial name
- NCT00356421
- Testing
- Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
- Where
- 23 sites in United States, Austria and 11 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the safety of pramlintide treatment using pramlintide dose-titration coupled with insulin adjustments in subjects with type 1 diabetes who…
- Trial name
- NCT00042458
- Testing
- Pramlintide acetate
- Where
- 33 sites in United States
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 (insulin degludec) in Japanese subjects with type 1 diabetes.
- Trial name
- NCT01135927
- Testing
- insulin degludec, insulin detemir
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Long-Term Outcomes of Teplizumab in Routine Clinical Care
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D.
- Trial name
- AL1GN (NCT07360080)
- Testing
- Teplizumab
- Where
- 10 sites in United States, Israel and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Insulin-dependent Diabetes Mellitus, Diabetes Mellitus, Type 1
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy
A multi center, open label, prospective study that will include up to 100 subjects with Type 1 Diabetes treated with Multiple Daily Injections (MDI) of insulin according to a predefined sliding scale plan or carbohydrate ratio…
- Trial name
- NCT04043260
- Testing
- Advisor Pro
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- DreaMed Diabetes
Type 1 Diabetes Mellitus
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.
- Trial name
- NCT03959423
- Testing
- AHCL insulin pump system
- Where
- 17 sites in United States
- Volunteers
- 288 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Type 1 Diabetes Mellitus
Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin
The purpose of this study is to determine if glucose peaks higher and earlier after a meal when a patient is given intranasal insulin instead of conventional insulin treatment.
- Trial name
- NCT00850161
- Testing
- aspart, Nasulin™
- Sponsor
- CPEX Pharmaceuticals Inc.
Type 1 Diabetes
Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes
This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
- Trial name
- NCT05495386
- Testing
- Hyposafe hypoglycaemia notification device (H02)
- Sponsor
- UNEEG Medical A/S
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT02527265
- Testing
- Afrezza
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965509
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 1 Diabetes
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.
- Trial name
- NCT05683392
- Testing
- t:slim X2 insulin pump with Control-IQ technology 2.0
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes Mellitus
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
- Trial name
- NCT01686620
- Testing
- BIOD-123, Lispro (Humalog)
- Where
- 34 sites in United States
- Volunteers
- 132 people
- Sponsor
- Biodel
T1D
Validation of a Computerised Adaptive Test for Measuring Caregiver Well-being
The main objective of this project is to test whether a tool (questionnaire) is suitable for assessing how caregivers of children and adolescents with TD1 feel emotionally and psychologically.
- Trial name
- NCT06999486
- Testing
- CAT well-being test
- Where
- Spain
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Type 1 Diabetes Mellitus
Bigfoot Biomedical Clinical Research Center (CRC) Trial
The trial is designed to assess safety and feasibility of the Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS) in up to 50 participants in a closely monitored Clinical Research Center (CRC) environment.
- Trial name
- NCT02849288
- Testing
- Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bigfoot Biomedical Inc.
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.